TLSIW — TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc. (TLSIW) common stock listed on NASDAQ. It is led by Mary T. Szela B.S.N., M.B.A., based in 6272 West 91st Avenue, Westminster, CO, United States, 80031, with about 102 employees. TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial for treating locally advanced pancreatic cancer. The company is also developing nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, and value analysis committee staff. The company was founded in 2009 and is headquartered in Westminster, Colorado.

Latest reported TLSIW revenue for 2025-09-30 was $11.6M. Net income was -$10.8M. Revenue was up 3.1% from 2025-06-30 to 2025-09-30.

Use this TLSIW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the TLSIW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the TLSIW SEC filings page. Lician reads the product cache first so this HTML stays unique to TriSalus Life Sciences Inc. even when a live quote feed is slow.